| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.8M | +7.0% |
| R&D Expense | $7.2M | -53.8% |
| SG&A Expense | $7.8M | +19.4% |
| Operating Income | -$9.8M | +33.8% |
| Net Income | -$9.6M | +32.3% |
| EPS (Basic) | -$2.62 | +32.3% |
| EPS (Diluted) | -$2.62 | +32.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $9.5M | -50.3% |
| Accounts Receivable | $928K | +0.0% |
| Current Assets | $9.9M | -52.4% |
| Total Assets | $9.9M | -70.7% |
| Current Liabilities | $929K | -76.2% |
| Total Liabilities | $996K | -93.8% |
| Stockholders' Equity | $8.9M | -50.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$10.7M | +33.0% |
| Capital Expenditures | $398K | -41.1% |
| Investing Cash Flow | -$398K | +41.1% |
| Financing Cash Flow | $53K | +0.0% |
| Free Cash Flow | -$11.1M | +33.3% |